Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF for PSA Progression in Prostate Cancer
NCT00678054Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Apr 1999
- Primary completion
- Aug 2000
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in prostate cancer (PCa), sponsored by University of California, San Francisco. Primary endpoint: Prostate Specific Antigen Response. Started Apr 1999; status: completed.
02
Drugs
sargramostim
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00678054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00678054.